Structural heart disease firm Micro Interventional Devices Inc. hopes to gain a CE mark and launch its clinical stage Permaseal transmyocardial access and closure device in Europe by the second half of 2013, with a focus on use for big-ticket transapical transcatheter aortic valve replacement procedures.
Permaseal, which the company calls the first transapical access device to enable true self-sealing, sutureless cardiac access and closure, is...